Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Stock-Based Comp

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s stock-based comp.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s stock-based comp?
Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $956.19K in Q1 2026.
How has Relmada Therapeutics, Inc.'s stock-based comp changed year-over-year?
Relmada Therapeutics, Inc.'s stock-based comp decreased by 73.2% year-over-year, from $3.57M to $956.19K.
What is the long-term trend for Relmada Therapeutics, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock-based comp has grown at a -23.4% compound annual growth rate (CAGR), from $40.49M to $13.91M.